A paper co-authored by Dr. NAKAGAMI Yuki Faculty of Data Science and others (The Department of Gastroenterology and Oncology, Graduate School of Medicine, Yamaguchi University, and joint research with Oncology Center, Yamaguchi University Hospital) has been published in an international journal. It was published by MDPI, an academic journal published by MDPI, which currently has a high impact factor in cancer-related research journals (IF: 6.575).

For more information, please refer to here.

https://www.mdpi.com/2072-6694/16/14/2522

Dissertation Information　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

Magazine name: Cancers

Title: Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Senior Patients with Pancreatic Cancer "Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX therapy for Elderly Pancreatic Cancer"

Author: Yoshitaro Shindo¹, Tatsuya Ioka², Yukio Tokumitsu¹, Hiroto Matsui¹, Masao Nakajima¹, Yuta Kimura¹, Yusaku Watanabe¹, Shinobu Tomochika¹, Yuki Nakagami^1,3, Ryouichi Tsunedomi¹, Michihisa Iida¹, Hidenori Takahashi¹, and Hiroaki Nagano¹

¹Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine

²Department of Oncology Center, Yamaguchi University Hospital

³Department of Data Science, Shimonoseki City University

Outline of research　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

Neoadjuvant chemotherapy (NAC) is known to be effective in improving prognosis for patients with resectable and resectable boundary pancreatic cancer (PC). Modified FOLFIRINOX (mFOLFIRINOX) therapy is widely used as a standard treatment, but its toxicity does not apply to patients over 75 years of age. Elderly patients are also more likely to have complications and are at high risk of adverse events associated with chemotherapy. Therefore, considering the rapid increase in the number of elderly patients, it is necessary to verify whether NAC is feasible for both non-elderly and elderly patients.

In this study, we examined the safety and feasibility of preoperative mFOLFIRINOX therapy for elderly pancreatic cancer, using advanced statistical modeling and survival time analysis. As a result, it was found that the perioperative and postoperative outcomes of older patients who received preoperative mFOLFIRINOX were similar to non-elderly patients. It has been suggested that preoperative mFOLFIRINOX is a feasible option for elderly pancreatic cancer.

[Date of publication: 2024.7.22]

[Contact]
Public university corporation Shimonoseki City University
Corporate Planning Department Public Relations and Branding Strategy Division
TEL. 083-253-8967